The development of RNA therapeutics for epilepsy will "change everything" because it opens up entirely new druggable targets and address the underlying causes of epilepsy, experts say.

Global Experts Launch New Medical Society to Promote Research, Education and Development in RNA Therapeutics

/PRNewswire/ -- Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader...

It is now possible to deliver therapeutics based on short interfering RNAs to hepatocytes; however, new delivery solutions are necessary to target additional organs. In a new report now published in Nature Biotechnology, a team of researchers including Kirk M. Brown, Jayaprakash K. Nair, and Maja M. Manas, led by Vasant Jadhav at Alnylam Pharmaceuticals Cambridge MA, U.S., discussed the safe conjugation of…

MIT Professor Xiao Wang's research is focused on developing tools that pinpoint where in a cell different types of messenger RNA are translated into proteins — information that can offer insight into how cells control their fate and what goes wrong in disease.

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A finan

Amit Munshi had to beg off when he was first introduced to the idea of running an MPM BioImpact stealth player named ReNAgade Therapeutics. He had just sold Arena to Pfizer for $6.7 billion — a deal that wrapped in the spring of last year — after getting a lot

MCI USA's Association Solutions division is pleased to welcome the Society for RNA Therapeutics as a new full-service association management client. The mission of the newly formed nonprofit scientific society is to promote research, education, and developments in RNA therapeutics to improve global health. RNA therapeutics have the potential to revolutionize numerous potential medical applications, including…

Orna Therapeutics is in the money. | Orna Therapeutics is in the money. Tuesday morning, the developer of fully engineered circular RNA therapies revealed a double dose of good news, simultaneously taking the lid off an alliance with Merck & Co. worth $150 million upfront and a $221 million series B financing.

/PRNewswire-PRWeb/ -- RNA technologies have revolutionized the field of therapeutics, enabling breakthroughs in vaccine development and gene therapy....

Using an RNA sensor, MIT engineers designed a new way to trigger cells to turn on a synthetic gene. Their approach could make it possible to create targeted therapies for cancer and other diseases, by ensuring that synthetic genes are activated only in specific cells.

Novo Nordisk, Amgen, CRISPR Therapeutics, and others are set to reveal potentially game-changing trial results this year

Alnylam said it was seeking compensation for use of its lipid nanoparticles (LNP) technology that carries and delivers RNA-based therapeutics or vaccines in ...

InstantGMP PRO Software allows the renowned RNA cell therapy company, Cartesian Therapeutics, to move from preclinical development to clinical testing more efficiently and effectively.

Transcription factors are known to bind DNA and protein, but new research shows many of them also bind RNA. The work, from MIT and the Whitehead Institute for Biomedical Research, illuminates an aspect of gene expression and suggests new therapeutic opportunities.

So, sea squirts. More elegantly known as ascidians, these early vertebrates metamorphose from tadpoles into their tube-like, immobile adult forms. To do that, ascidians edit their RNA — through a technique that former Biogen R&D chief and current ATP CSO Michael Ehlers has co-opted for his latest biotech, Ascidian Therapeutics.

The goals of the study are to generate new intellectual property around the potential diagnosis and treatment of neurological complications of Long COVID-19 and assess whether ATL1102, an RNA inhibitor being developed by Antisense Therapeutics, could also treat Long COVID-19.

How active compounds affect RNA and thus the expression of genes is of great interest for the development of potential therapeutics. Innsbruck chemists have now used a method they recently developed to study the binding of the aminoglycoside Neomycin B to a so-called mRNA riboswitch.

To treat genetic diseases, CAMP4 is targeting a type of RNA whose role in gene expression was first described by co-founder and MIT Professor Richard Young.

MIT scientists have uncovered ancient systems with potential to expand the genome editing toolbox. These tandem interspaced guide RNA (TIGR) systems use RNA to guide them to specific sites on DNA.